[关键词]
[摘要]
目的 观察心悦胶囊联合琥珀酸美托洛尔缓释片治疗冠心病心绞痛的临床疗效。方法 选取2018年4月—2021年2月郑州大学第一附属医院收治的136例冠心病心绞痛患者作为观察对象,根据随机数字表法分为对照组(68例)和治疗组(68例)。对照组口服琥珀酸美托洛尔缓释片,1片/次,1次/d。治疗组患者在对照组治疗的基础上口服心悦胶囊,2粒/次,3次/d。两组治疗疗程均为4周。观察两组临床疗效、心电图疗效,比较两组心绞痛症状、心功能指标、心肌损伤指标、血液流变学指标。结果 治疗后,治疗组的临床疗效总有效率为94.12%,高于对照组的80.88%,治疗组的心电图疗效总有效率为92.65%,高于对照组的76.47%,组间对比差异有统计学意义(P<0.05)。治疗后,两组心绞痛发作频率降低、持续时间缩短(P<0.05),与对照组相比,治疗后治疗组心绞痛发作频率降低、持续时间缩短更显著(P<0.05)。治疗后,两组左心室射血分数(LVEF)、心排血量(CO)较治疗前升高(P<0.05),与对照组相比,治疗后治疗组的LVEF、CO升高更显著(P<0.05)。治疗后,两组全血低切黏度、全血高切黏度、血浆黏度、纤维蛋白原较治疗前降低(P<0.05)。与对照组相比,治疗后治疗组全血低切黏度、全血高切黏度、血浆黏度、纤维蛋白原降低更显著(P<0.05)。治疗后,两组肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)、脑钠肽(BNP)水平较治疗前降低(P<0.05),与对照组相比,治疗后治疗组CK-MB、cTnI、BNP水平降低更显著(P<0.05)。结论 心悦胶囊联合琥珀酸美托洛尔缓释片治疗冠心病心绞痛具有较好的临床疗效,能够改善血液流变学、心功能,减轻心肌损伤,安全性好。
[Key word]
[Abstract]
Objective To observe the therapeutic effect of Xinyue Capsules combined with Metoprolol Succinate Sustained-release Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (136 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Zhengzhou University from January 2013 to February 2015 were randomly divided into the control group (68 cases) and the treatment group (68 cases). Patients in the control group were po administered with Metoprolol Succinate Sustained-release Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xinyue Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies and electrocardiogram efficacies were evaluated, and the symptoms of angina pectoris, the cardiac function indexes, the myocardial injury indexes, and the hemorheological indexes in two groups were compared. Results After treatment, the clinical effective rate in the treatment group was 94.12%, which was higher than 80.88% in the control group, and the electrocardiogram effective rate in the treatment group was 92.65%, which was higher than 76.47% in the control group, and there was significant difference between the groups (P < 0.05). After treatment, the attack frequency and duration of angina pectoris in two groups were decreased (P < 0.05). And compared with the control group, the attack frequency of angina pectoris was lower in the treatment group, and the duration of angina pectoris in the treatment group was significantly shortened (P< 0.05). After treatment, the LVEF and CO in two groups were higher than those before treatment (P < 0.05). And compared with the control group, the LVEF and CO in the treatment group increased more significantly after treatment (P < 0.05). After treatment, the whole blood low shear viscosity, whole blood high shear viscosity, plasma viscosity, and fibrinogen in two groups were lower than those before treatment (P < 0.05). And compared with the control group, the whole blood low shear viscosity, whole blood high shear viscosity, plasma viscosity, and fibrinogen in the treatment group decreased more significantly after treatment (P < 0.05). After treatment, the levels of CK-MB, cTnI, and BNP in two groups were lower than those before treatment (P < 0.05). And compared with the control group, the levels of CK-MB, cTnI, and BNP in the treatment group decreased more significantly after treatment (P < 0.05). Conclusion Xinyue Capsules combined with Metoprolol Succinate Sustained-release Tablets has clinical curative effect in treatment of angina pectoris of coronary heart disease, can improve hemorheology and cardiac function, reduce myocardial injury, with good safety.
[中图分类号]
R972
[基金项目]
河南省医学科技攻关计划项目(201601082)